488 related articles for article (PubMed ID: 7604807)
41. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
[TBL] [Abstract][Full Text] [Related]
43. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
Peters TK; Muratti EN; Mehra M
Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
Mabuchi H; Koizumi J; Kajinami K
Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
[TBL] [Abstract][Full Text] [Related]
45. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
Hailer S; Pogarell O; Keller C; Wolfram G
Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
[TBL] [Abstract][Full Text] [Related]
46. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
47. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
Herd JA
Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
[TBL] [Abstract][Full Text] [Related]
48. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
49. The patient at risk: who should we be treating?
Shviro I; Leitersdorf E
Br J Clin Pract Suppl; 1996 Jan; 77A():24-7. PubMed ID: 8729587
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
Jacotot B; Banga JD; Pfister P; Mehra M
Br J Clin Pharmacol; 1994 Sep; 38(3):257-63. PubMed ID: 7826828
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia.
Leitersdorf E; Eisenberg S; Eliav O; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Peters TK; Muratti EN
Eur J Clin Pharmacol; 1993; 45(6):513-8. PubMed ID: 8157036
[TBL] [Abstract][Full Text] [Related]
52. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
[TBL] [Abstract][Full Text] [Related]
53. Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia.
Leitersdorf E
Drugs; 1994; 47 Suppl 2():54-8. PubMed ID: 7517834
[TBL] [Abstract][Full Text] [Related]
54. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
55. Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation.
Lal SM; Gupta N; Georgiev O; Ross G
Int J Artif Organs; 1997 Jan; 20(1):18-21. PubMed ID: 9062827
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
[TBL] [Abstract][Full Text] [Related]
57. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Vergoulas G; Miserlis G; Solonaki F; Imvrios G; Gakis D; Papanikolaou V; Papagiannis A; Visvardis G; Takoudas D; Antoniadis A
Transpl Int; 2000; 13 Suppl 1():S64-7. PubMed ID: 11111964
[TBL] [Abstract][Full Text] [Related]
58. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.
Farnier M; Dejager S
Am J Cardiol; 2000 Jan; 85(1):53-7. PubMed ID: 11078237
[TBL] [Abstract][Full Text] [Related]
59. Fluvastatin titrate-to-goal clinical practice study.
Weiss RJ
Am J Ther; 1998 Sep; 5(5):281-5. PubMed ID: 10099070
[TBL] [Abstract][Full Text] [Related]
60. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
